CHICAGO — Undetectable EGFR mutations in plasma 3 to 6 weeks after treatment with a tyrosine kinase inhibitor appears to be a prognostic factor of improved PFS among patients with advanced, EGFR-mutated non-small cell lung cancer, according to a new analysis of data from the phase 3 FLAURA trial.

The results further showed that patients who received osimertinib (Tagrisso, AstraZeneca) had significantly longer PFS vs. those who received a comparator TKI, regardless of their mutation clearance status.